One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
PerkinElmer logo
PerkinElmer PKI
report update icon

Quarterly report 2026-Q2
added 08-11-2026

PerkinElmer Cash Flow 2025-2007 | PKI

Brief cash flow overview of PerkinElmer

Cash flow changes are traced through the five latest available reports from 2021 to 2025.

Core cash generation deteriorated, ending at $582.9 million versus $892.2 million at the beginning.

Each of the five years produced positive cash from operations, indicating stable cash generation.

Each unit of cumulative profit produced roughly 1.58x of operating cash flow. Earnings quality looks high.

Operating cash flow margin declined from 103.6% to 20.4%. Revenue converted into cash less effectively.

Receivables and inventory net of payables decreased $388.1 million, supporting cash flow.

Overall assessment

PerkinElmer's cash flows are broadly resilient, though selected ratios need monitoring. Positive earnings conversion and moderate investment demand remain important.

Annual Cash Flow PerkinElmer

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2008 2007

Operating Cash Flow

583 M 628 M 91.3 M 1.41 B 892 M - 363 M 311 M 288 M 287 M - 282 M 159 M 152 M 164 M 149 M 218 M -

Depreciation & Amortization

405 M 428 M 432 M 311 M 202 M - 214 M 181 M 105 M 105 M - 110 M 127 M 125 M 89.2 M 80.8 M 77.4 M -

Accounts Payables

185 M 167 M 204 M 325 M 327 M - 236 M 221 M 222 M 153 M - 174 M 167 M 169 M 161 M 134 M - -

Accounts Receivables

783 M 661 M 662 M 738 M 1.18 B - 745 M 633 M 552 M 439 M - 471 M 470 M 457 M 357 M 320 M - -

Total Inventories

379 M 368 M 428 M 426 M 515 M - 357 M 338 M 352 M 288 M - 285 M 261 M 248 M 207 M 179 M - -

All numbers in USD currency

Quarterly Cash Flow PerkinElmer

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2

Operating Cash Flow

- 115 M - - - 128 M - - - 148 M - - - 63.5 M - 541 M 381 M 283 M - 1.08 B 761 M 474 M - 410 M 199 M 60 M - 148 M 41.5 M -5.32 M - 152 M 58.4 M -14.6 M - 160 M 102 M 53.7 M - 202 M 128 M 32 M - 162 M 101 M 37.7 M - 185 M 122 M 67.7 M - 86.9 M 38.8 M 10.9 M - 113 M 91.9 M 15.5 M - 142 M 94.6 M 42.7 M - 135 M 120 M

Depreciation & Amortization

85.3 M 105 M - 18 M 17.5 M 97.4 M - 18 M 16.7 M 108 M - 90.9 M 92.8 M 109 M - 91.5 M 93.7 M 109 M - 197 M 146 M 70.2 M - 183 M 120 M 60.8 M - 157 M 104 M 50.5 M - 133 M 88.2 M 44.5 M - 75.5 M 49.5 M 24.7 M - 74.5 M 50.2 M 25.4 M - 83.8 M 56.6 M 28.3 M - 86.8 M 57.9 M 29.3 M - 95.2 M 62 M 30.6 M - 94.8 M 64.2 M 32 M - 78.7 M 50.6 M 24 M - 65.9 M 48.5 M

Accounts Payables

185 M 170 M 167 M 176 M 178 M 178 M 167 M 176 M 175 M 184 M 204 M 188 M 236 M 267 M 273 M 276 M 334 M 377 M 327 M 320 M 325 M 339 M - 258 M 255 M 233 M 236 M 236 M 236 M 236 M 221 M 221 M 221 M 221 M 222 M 222 M 222 M 222 M 141 M 162 M 156 M 159 M - 150 M 171 M 157 M 174 M 174 M 174 M 174 M 167 M 167 M 167 M 167 M 169 M 169 M 169 M 169 M 161 M 151 M 149 M 149 M 134 M 143 M 175 M

Accounts Receivables

745 M 691 M 632 M 680 M 661 M 617 M 632 M 602 M 597 M 589 M 633 M 645 M 627 M 587 M 613 M 541 M 932 M 942 M 1.18 B 948 M 993 M 979 M - 798 M 709 M 626 M 745 M 725 M 725 M 725 M 633 M 633 M 633 M 633 M 552 M 552 M 552 M 552 M 415 M 443 M 436 M 437 M - 414 M 426 M 415 M 471 M 471 M 471 M 471 M 467 M 467 M 467 M 470 M 457 M 457 M 457 M 457 M 357 M 360 M 383 M 345 M 320 M 324 M 365 M

Total Inventories

379 M 388 M 368 M 380 M 388 M 381 M 368 M 405 M 401 M 414 M 428 M 436 M 437 M 429 M 405 M 378 M 624 M 646 M 515 M 645 M 513 M 530 M - 487 M 478 M 393 M 357 M 357 M 357 M 357 M 338 M 338 M 338 M 338 M 352 M 352 M 352 M 352 M 259 M 306 M 300 M 314 M - 313 M 305 M 291 M 285 M 285 M 285 M 285 M 261 M 261 M 261 M 261 M 248 M 248 M 248 M 248 M 207 M 229 M 222 M 225 M 179 M 210 M 232 M

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company PerkinElmer, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Diagnostics research sector

Issuer Price % 24h Market Cap Country
CareDx, Inc CareDx, Inc
CDNA
$ 64.0 3.07 % $ 3.41 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 20.15 3.33 % $ 451 M usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 229.04 3.04 % $ 163 B usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 25.74 0.98 % $ 24.4 B niderlandNiderland
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 11.44 2.69 % $ 389 M israelIsrael
Precipio Precipio
PRPO
$ 21.38 1.3 % $ 34.3 M usaUSA
RadNet RadNet
RDNT
$ 68.8 1.81 % $ 5.17 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 31.96 2.08 % $ 926 M usaUSA
Guardant Health Guardant Health
GH
$ 158.6 1.77 % $ 19.9 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 7.77 1.6 % $ 324 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 4.82 0.97 % $ 19.2 M israelIsrael
DexCom DexCom
DXCM
$ 86.04 0.07 % $ 33.6 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 266.9 0.11 % $ 45.9 B usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.18 5.31 % $ 22.6 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
$ 436.95 0.65 % $ 26 B usaUSA
Exagen Exagen
XGN
$ 7.72 1.66 % $ 166 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.25 0.36 % $ 6.81 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.18 3.65 % $ 13.3 B irlandaIrlanda
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.85 6.81 % $ 3.82 M usaUSA
OPKO Health OPKO Health
OPK
$ 1.53 0.62 % $ 1.15 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 690.0 3.46 % $ 260 B usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 132.75 0.45 % $ 7.94 B usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 17.89 0.03 % $ 5.08 B usaUSA
Natera Natera
NTRA
$ 393.44 2.54 % $ 53.8 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
$ 46.13 0.15 % $ 10 B niderlandNiderland
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 8.03 1.26 % $ 2.88 B irlandaIrlanda
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.0 0.36 % $ 26.1 B usaUSA
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 560.36 2.41 % $ 45.1 B usaUSA
Personalis Personalis
PSNL
$ 15.65 0.19 % $ 1.4 B usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 6.47 2.11 % $ 28.6 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
$ 1.85 3.0 % $ 5.39 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 3.98 4.82 % $ 369 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.73 0.73 % $ 519 M usaUSA